Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

105.97 -0.76 (-0.71%)
Streaming Delayed Price Updated: 12:29 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH. 
Via Benzinga
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences
Via Benzinga
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
Why Neurocrine Biosciences Stock Sank Today
Via The Motley Fool
Why the quality investor may take a look at NASDAQ:NBIX.
A fundamental analysis of (NASDAQ:NBIX): Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Based on Fundamental Analysis it can be said that NASDAQ:NBIX is a growth stock which is not overvalued. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Via The Motley Fool
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Earnings Summary: Neurocrine Biosciences Q4
Via Benzinga
Earnings Scheduled For February 6, 2025
Via Benzinga
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Despite its growth, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) remains within the realm of affordability.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
NASDAQ:NBIX is showing decent growth, but is still valued reasonably.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?
Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to... 
Via Benzinga
NASDAQ:NBIX: good value for what you're paying.
Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges. 
Via Benzinga
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. 
Via Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal. 
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.